The KCa3.1 blocker TRAM-34 in contrast should primarily affect the smooth muscle and fibroproliferative component of the disease based on previous findings that the compound prevents restenosis following balloon angioplasty in rats [18] and pigs [19], kidney fibrosis in mice and rats [20], and atherosclerosis development in ApoE−/− mice [21]. This evidence concerns the gene KCNN4 and atherosclerosis.